Inspiris瓣膜行肺动脉瓣置换术的短期与中期结果
本研究回顾了2007年至2022年在斯坦福大学露西尔·帕卡德儿童医院接受19-29mm Inspiris或Mosaic瓣膜行肺动脉瓣置换术的225例连续患者,比较短期和中期结局。结果显示两组早期术后压差均较低但Mosaic组更高,Inspiris瓣膜随时间推移发生中度及以上肺动脉瓣反流的可能性显著更高,而再干预率和最大压差≥36 mmHg无显著差异。
要点
- Inspiris瓣膜行肺动脉瓣置换术后发生中度及以上肺动脉瓣反流的风险显著高于Mosaic瓣膜。
- 两组再干预率和最大压差≥36 mmHg无显著差异。
- Inspiris瓣膜在肺动脉位置的耐久性可能不优于其他生物瓣膜。
核心结论
- Inspiris和Mosaic瓣膜行肺动脉瓣置换术的早期和短期压差相似,但接受Inspiris瓣膜的患者发生显著肺动脉瓣反流更常见。
- 这些初步发现提示Inspiris瓣膜在肺动脉位置的耐久性可能不优于其他用于肺动脉瓣置换的生物瓣膜。
研究设计与样本
- 本研究回顾了2007年至2022年在斯坦福大学露西尔·帕卡德儿童医院(美国加利福尼亚州帕洛阿尔托)接受19-29mm Inspiris瓣膜或Mosaic瓣膜行肺动脉瓣置换术的所有患者。
- 共纳入225例连续患者,其中Mosaic瓣膜组163例,Inspiris瓣膜组62例。
- 中期结局包括免于中度或重度肺动脉瓣反流、最大多普勒压差≥36 mmHg以及免于再干预。
主要发现
- 两组基线特征无差异。
- 早期术后压差在两组均较低,但Mosaic组更高。
- 出院时两组均无超过轻度的肺动脉瓣反流。
- 单变量和多变量分析显示,Inspiris瓣膜随时间推移发生中度及以上肺动脉瓣反流的可能性显著更高。
- 两组在免于再干预或免于最大压差≥36 mmHg方面无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various bioprosthetic valves are used off-label for pulmonary valve replacement (PVR), but there is no consensus on whether a particular valve is best for this application. Recently, the Inspiris Resilia valve (Edwards Lifesciences Inc) was approved for aortic valve replacement, and surgeons have begun using it for PVR. There is limited evidence on the performance of the Inspiris valve compared with other valves in the pulmonary position. METHODS: This study reviewed all patients who underwent PVR with a size 19- to 29-mm Inspiris valve or Mosaic valve (Medtronic Inc) from 2007 to 2022 at Lucile Packard Children's Hospital Stanford (Palo Alto, CA). Midterm outcomes included freedom from moderate or severe pulmonary regurgitation (PR), a maximum Doppler gradient ≥36 mm Hg, and freedom from reintervention. RESULTS: A total of 225 consecutive patients who underwent PVR with a size 19- to 29-mm Mosaic (n = 163) or Inspiris (n = 62) valve were included. There was no difference in baseline characteristics. Early postoperative gradients were low in both groups but higher in the Mosaic cohort, and neither group had more than mild PR on discharge. On univariable and multivariable analysis, Inspiris valves were significantly more likely to develop moderate or greater PR over time. There was no significant difference between the valves in freedom from reintervention or from a maximum gradient ≥36 mm Hg. CONCLUSIONS: Early and short-term gradients were similar in patients undergoing PVR with Inspiris and Mosaic valves, but significant PR was more common in patients who received an Inspiris valve. These preliminary findings suggest that the durability of the Inspiris valve in the pulmonary position may not be superior to that of other bioprosthetic valves used for PVR.
引用
- Ragheb DK, Martin E, Jaggi A, et al. Short- and Mid-Term Results of Pulmonary Valve Replacement with the Inspiris Valve. Ann Thorac Surg. 2023. PMID: 37625611. doi:10.1016/j.athoracsur.2023.07.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。